Phospholipase a2 is an inflammatory predictor in cardiovascular diseases: Is there any spacious room to prove the causation?

Anwar Santoso, Teuku Heriansyah, Mohammad S. Rohman

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)

Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme family of phospholipase A2 produced by the inflammatory cell in atherosclerotic plaque. It is transported in the circulation, attached mainly to low-density lipoprotein-cholesterol (LDL-C). It hydrolyzes glycerophos-pholipids particularly fatty acids at the sn-2 position and produces numerous bioactive lipids; and leads to endothelial dysfunction, atherosclerotic plaque inflammation, and development of the necrotic core in plaques. There are two kinds of phospholipase A2, namely: secretory phospholipase A2 (sPLA2) and Lp-PLA2. They are deemed as evolving predictors of cardiovascular disease (CVD) risk in hospital-and population-based studies, including healthy subjects, acute coronary syndromes (ACS) and patients with CVD. Unfortunately, Lp-PLA2 inhibitor (darapladib) and s-PLA2 inhibitor (varespladib methyl) failed to prove to lower the risk of composite CVD mortality, myocardial infarction and stroke in those with stable CVD and ACS. Herein, we describe the explanation based on the existing data why there is still a discrepancy among them. So, it highlights the opinion that phospholipase A2 is merely the inflammatory biomarkers of CVD and playing an important role in atherosclerosis. Further, there is more spacious room to prove the causation.

Original languageEnglish
Pages (from-to)3-10
Number of pages8
JournalCurrent Cardiology Reviews
Volume16
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • Acute coronary syndromes
  • Atherosclerosis
  • Cardiovascular disease
  • LDL-C
  • Lipoprotein-associated phospholipase A
  • Myocardial infarction

Fingerprint Dive into the research topics of 'Phospholipase a<sub>2</sub> is an inflammatory predictor in cardiovascular diseases: Is there any spacious room to prove the causation?'. Together they form a unique fingerprint.

Cite this